The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer | Zendy

Maria A. Voronkova | Zendy; Liying W. Rojanasakul | Zendy; Chayanin Kiratipaiboon | Zendy; Yon Rojanasakul | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer

Author(s) -

Maria A. Voronkova,

Liying W. Rojanasakul,

Chayanin Kiratipaiboon,

Yon Rojanasakul

Publication year - 2019

Publication title -

molecular and cellular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.14

H-Index - 327

eISSN - 1067-8824

pISSN - 0270-7306

DOI - 10.1128/mcb.00307-19

Subject(s) - biology , cisplatin , cancer research , cancer stem cell , gene knockdown , lung cancer , aldehyde dehydrogenase , transcription factor , chromatin immunoprecipitation , stem cell , chemotherapy , apoptosis , medicine , microbiology and biotechnology , promoter , gene expression , genetics , enzyme , biochemistry , gene

Chemotherapy resistance and tumor relapse are the major contributors to low patient survival, and both have been largely attributed to cancer stem-like cells (CSCs) or tumor-initiating cells (TICs). Moreover, most conventional therapies are not effective against CSCs, which necessitates the discovery of CSC-specific biomarkers and drug targets.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research